Zobrazeno 1 - 10
of 11 097
pro vyhledávání: '"Anti-VEGF"'
Publikováno v:
Clinical Ophthalmology, Vol Volume 18, Pp 3097-3102 (2024)
Yaqoob Qaseem,1 Kirk Kohwa Hou,1,2 Moritz S Pettenkofer1 1Retina Division, Stein Eye Institute, University of California Los Angeles, Los Angeles, CA, USA; 2Doheny Eye Institute, Los Angeles, CA, USACorrespondence: Moritz S Pettenkofer, Retina Divisi
Externí odkaz:
https://doaj.org/article/1edfd16d254b4e68a57ea1aa4ab89684
Publikováno v:
Clinical Ophthalmology, Vol Volume 18, Pp 2939-2949 (2024)
Bhim B Rai,1,2 Phuntsho Dorji,2 Ted Maddess1 1John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia; 2Department of Ophthalmology, JDW National Referral Hospital, Thimphu, BhutanCorrespondence: Bhim B Rai, B
Externí odkaz:
https://doaj.org/article/fdb92bc26b3e4da88a7f60b2db184662
Autor:
Stefan Knop, Monika Szarejko, Norbert Grząśko, Sara Bringhen, Karolin Trautmann‐Grill, Artur Jurczyszyn, Angelo Vacca, Cyrus Khandanpour, Barbara Gamberi, Ludek Pour, Katrine F. Iversen, Michael T. Stumpp, Cosima Suter, Keith M. Dawson, Christof Zitt, Philippe Legenne, Vaia Stavropoulou, Martin F. Fey, Nicolas Leupin, Hartmut Goldschmidt
Publikováno v:
eJHaem, Vol 5, Iss 5, Pp 940-950 (2024)
Abstract MP0250 is a designed ankyrin repeat protein that specifically inhibits both vascular endothelial growth factor A (VEGF‐A) and hepatocyte growth factor (HGF), aiming at potentiating cancer therapy by disrupting the tumour microenvironment.
Externí odkaz:
https://doaj.org/article/d9320941c5f7443ea0d680430869e3d7
Publikováno v:
BMC Ophthalmology, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background This study aims to evaluate the two-year outcomes of polypoidal choroidal vasculopathy (PCV) treated with conbercept and to investigate the predictive response factors. Methods Consecutive patients with PCV who received three-load
Externí odkaz:
https://doaj.org/article/72075e253d61471490b4f966cd16d6b8
Autor:
Hyo Song Park, Seung Won Lee, Hyunjin Park, Nang Kyeong Lee, Yong Joon Kim, Christopher Seungkyu Lee, Suk Ho Byeon, Sung Soo Kim
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract This study aimed to evaluate the incidence of clinically significant intraocular inflammation (csIOI) after treatment with intravitreal injection (IVI) of brolucizumab and identify csIOI risk factors. We categorized 60,966 South Korean patie
Externí odkaz:
https://doaj.org/article/868bec7543624ead84117fc550d9bdf1
Publikováno v:
Ophthalmology and Therapy, Vol 13, Iss 11, Pp 2887-2901 (2024)
Abstract Introduction Despite the wide range of treatment options available for diabetic macular edema (DME), adherence to treatment remains a barrier. Therefore, this study used conjoint analysis to examine the factors that patients with DME priorit
Externí odkaz:
https://doaj.org/article/d4210ce494f34283af254d52f12a18f7
Autor:
Giuseppe Cancian, Arianna Paris, Lia Agliati, Angelica Rizzato, Michele Clerici, Giulio Volpe, Moreno Menghini, Gabriela Grimaldi
Publikováno v:
Ophthalmology and Therapy, Vol 13, Iss 11, Pp 2985-2997 (2024)
Abstract Introduction This study assessed the efficacy, durability, and safety of faricimab in patients with neovascular age-related macular degeneration (nAMD), previously treated with aflibercept or ranibizumab with unsatisfactory results. Methods
Externí odkaz:
https://doaj.org/article/a6323d151415440f8d88022e184993fe
Autor:
G. V. Zaychenko, V. P. Rozumnyi
Publikováno v:
Journal of Ophthalmology, Iss 4, Pp 58-64 (2024)
The incidence of blindness due to exudative retinal diseases reduced significantly over the twenty years of the use of anti-vascular endothelial growth factor (VEGF) therapy in ophthalmology. However, despite advances in recent years, current outcome
Externí odkaz:
https://doaj.org/article/8271104a31624c1ab65b0dea06f083ef
Publikováno v:
BMC Ophthalmology, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Topical non-steroidal anti-inflammatory drugs have the potential to reduce treatment burden and improve outcomes of anti-VEGF therapy for a number of retinal disorders, including neovascular age-related macular degeneration, diabe
Externí odkaz:
https://doaj.org/article/9be5d565b34d446aaef39df9b19c67f6
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 8, Iss 1, Pp 1-8 (2024)
Abstract Background Neovascular age-related macular degeneration (nAMD) is a common cause of visual impairment and blindness in the elderly with globally increasing prevalence. Vascular endothelial growth factor inhibitor (anti-VEGF) treatment has im
Externí odkaz:
https://doaj.org/article/af729b8afe89471aa7dfe60bae959279